ZVRA

Zevra Therapeutics, Inc. Common Stock
Data: 2026-08-03

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Quick Stats
Aug 03, 2026

54.6

AI Score

HOLD

1.13

Volume Ratio

Aug 05, 2026

Next Earnings

16

+ve Days (30d)

14

-ve Days (30d)

ZVRA Stock Summary

Last updated Aug 03, 2026

ZVRA is currently trading at $10.055, positioned below its 200-day moving average of $10.11, suggesting bearish momentum. The stock has a 52-week range of $7.16 to $15.035.

Technical Analysis: The 50-day moving average stands at $12.19, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 35.678, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.085, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates ZVRA at 54.6/100 with a HOLD recommendation.

ZVRA (Zevra Therapeutics, Inc. Common Stock) Indicators

Last updated Aug 03, 2026

Indicator Value
RSI(14) 35.678
CMF (20) 0.085
ROC (10) -16.417
ADX (14) 33.965
Indicator Value
MACD (12,26,9) -0.864
AROONOSC (14) -57.143
WILLAMS %R (14) -76.361
MFI (14) 28.431
ZVRA Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

ZVRA Price vs Max Options Open Interest
ZVRA Max Change In Options Open Interest

ZVRA Options - Sort by Max open Interest (near term)

4th August 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

ZVRA Daily Out of Money Options - Sort by Max open Interest (near term)

4th August 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

ZVRA Daily In the Money Options - Sort by Max open Interest (near term)

4th August 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

ZVRA Most Active Options by Volume(near term)

4th August 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

Zevra Therapeutics, Inc. Common Stock is below both the 50 Day and 200 Day SMA which is considered Bearish.

ZVRA Moving Averages Analysis

ZVRA (Zevra Therapeutics, Inc. Common Stock) Simple Moving Averages

Moving Averages are last updated Aug 03, 2026

Days MA
10 10.51
20 11.92
30 12.46
50 12.19
100 11.12
200 10.11

ZVRA Fundamental Analysis

P/E (Forward) 8.7642
P/E (Trailing) 4.7313
Market Cap ($) 562.2 million
Earnings/Share ($) 2.01
Net Profit Margin (%) 1.0158
Dividend/Share ($) --
EPS Estimate Current Year ($) 1.2333
EPS Estimate Next Year ($) 1.055
WallStreet Target Price ($) 25.00
Most Recent Quarter